Introduction
In thalassemia major, lifelong need for medical care can have a major impact on physical and psychosocial well-being and quality of life (QoL) of patients and their families. 1 Unrelated donor bone marrow transplantation (BMT) in adult patients with thalassemia belonging to class-3 of the Pesaro classification (patients with presence of hepatomegaly, portal fibrosis and a history of irregular iron chelation), is burdened by an elevated transplant-related mortality (TRM, equal to 29% as reported in the most recently published paper). 2, 3 For this reason, these patients without an HLA-identical sibling need to make a difficult and radical decision. They can either continue traditional transfusion and chelation therapy, with no chance of complete recovery, or they can accept the high risk of TRM in the hope of obtaining a definitive elimination of the disease with prevention/reversion of its complications. The patients and their families who are faced with this decision need to have an exhaustive and honest description of all aspects related to transplantation, the perspectives of recovery of health and the global expectations of QoL in terms of physical and psychosocial well-being.
In this study, we evaluated 19 surviving adult thalassemia patients transplanted from an unrelated donor, investigating pre-transplantation communication and post transplantation QoL, emphasizing some ethical aspects of the decisional process.
Patients and methods

Patients and procedures
Twenty-seven consecutive adult class-3 thalassemia patients (15 males and 12 females) aged more than 16 years (median 22, range 17-37) were transplanted from an unrelated donor after a myeloablative regimen in four different Italian BMT centers. In a previous study, we reported the Kaplan-Meier probabilities of survival and event-free survival (70.4%), rejection (3.8%) and transplanted-related mortality (29.6%) of this cohort of patients. 3 Eight patients died after a median of 153 days (range 17-470) from BMT. Among the 19 surviving, transfusion-independent patients, four (21.5%) developed limited chronic graft-versus-host disease (GVHD). The median follow-up of surviving patients was 43 months (range 16-137).
Questionnaires
After obtaining written informed consent, questionnaires were either mailed or given personally to patients. All 19 surviving patients (11 males and 8 females, median age 23 years) were administered two different questionnaires 300 or more days from BMT: a questionnaire aimed at evaluating pre-transplantation communication factors and a second questionnaire, created by the European Organization for Research and Treatment of Cancer (EORTC) QoL study group and called the EORTC QLQ-C30 questionnaire, 4 designed to assess global QoL.
Communication factors and satisfaction for the choice of BMT The first questionnaire contained nine items and was developed in collaboration with an expert psychologist to investigate communication and global satisfaction for the decision of undergoing BMT. Patients were asked to recall the time when they were first informed of the possibility of BMT. The first item of the questionnaire measured degree of satisfaction for the decision to undergo BMT as excellent, good, satisfactory, inadequate or poor. The other eight items with dichotomous response categories investigated whether the information about the procedure and the mortality risk had been clearly and exhaustively presented; the BMT decision had been taken by the patient or his/her relatives; the patient had been given the opportunity to ask questions about his/her transplantation; the patient had asked for psychological support; the physician had talked about the QoL that could be expected.
Quality of life
To evaluate the global QoL, patients received the QLQ-C30 questionnaire, which is a validated multidimensional 30-item questionnaire to assess self-reported QoL. 4 This questionnaire is composed of scales evaluating physical, emotional, cognitive, role and social functions, and the global quality of life. Three symptom scales evaluated nausea and vomiting, pain and fatigue, whereas six single items assessed dyspnoea, diarrhea, constipation, appetite loss, sleep disturbances and financial difficulties. The response categories were either dichotomous such as 'yes' or 'no', or with four categories: 'not at all', 'a little', 'quite a bit', 'very much' or distributed on a modified visual analog scale from 1 to 7. All scores were linearly transformed to a 0-100 scale. 
Statistical analysis
Results
Questionnaires
The two questionnaires administered to the surviving patients were returned after a median of 37 days. All 19 patients who survive and are transfusion-independent returned the questionnaires, compiled in all the items, at a median time of 1016 days after BMT (range 300-4029). The median age at time of compiling the questionnaire was 24 years.
Communication factors and satisfaction for the choice of BMT Table 1 presents the results obtained with the questionnaire used to investigate communication factors. Seventeen out of 19 patients (89%) reported excellent or good levels of satisfaction for the decision to undergo BMT. The majority of patients reported that the physician had provided them with exhaustive information on the transplantation procedure and all of them were satisfied with the information concerning the risk of death. All patients reported that the information had been clearly presented. Sixteen patients felt that they had been able to ask questions about the BMT procedure. All patients but one reported that they Decision-making in transplantation for thalassemia G Caocci et al had been well informed by the physician about the QoL which was expected. Thirteen patients reported the need to discuss the decision for BMT with relatives and 14 expressed the need for psychological support before, during and after the transplantation procedure (see also Table 1 for further details).
Quality of life
The results of the QLQ-C30 survey are shown in Table 2 for further details). Three patients (16%) suffered severely from at least one symptom and eight (42%) from two or more moderate symptoms. Table 3 presents separately the results obtained in the groups with or without chronic GVHD. In the group of patients who developed chronic GVHD, the global QoL was good (mean score 65.3), whereas in those who did not develop GVHD the score was very good (mean 81.9). However, the difference in global health status between the two groups was not statistically significant. The variables for which patients without chronic GVHD had a significantly better value were physical function, emotional function, pain and insomnia.
Discussion
Communication factors
Exploration of communication strategies between physician and patient/relatives may lead to a better understanding of factors playing a role in transplantation. In fact, patients who are satisfied with communication are more capable of coping with treatment-related stress. 5 The importance of imparting individually tailored information has been emphasized by several authors, [6] [7] [8] but so far no study has been performed on thalassemia patients to investigate communication factors and patient satisfaction for BMT. Patients were asked to remember their experience before undergoing BMT. All patients reported that they had received sufficient information about the risk of transplant-related death. According to all patients, the information received had been clearly presented, particularly that concerning the QoL expectancy and the cure rate. However, in 16% of patients some information had been perceived as not completely exhaustive, and another 16% of patients felt that they had not been able to ask questions about their transplant. These data suggest that communication between the physician and patients or relatives could be further improved. Particular attention should be paid to the patient's level of understanding.
We also found that the patients in this study were satisfied with the choice of undergoing BMT. Only 32% of the patients did not report the need to discuss the decision with their relatives. Nevertheless, social and family support were generally recognized as a valuable coping resource.
Quality of life
Good QoL is defined as a state of physical, psychosocial well-being, in which the individual is able to perform everyday activities and reports satisfaction with daily function. 6 A number of studies have directly focused on the QoL of patients with a diagnosis of cancer undergoing BMT or thalassemia major patients treated with regular blood transfusion and iron-chelation therapy. [9] [10] [11] [12] [13] [14] [15] [16] However, no studies have been performed on the QoL of patients transplanted for thalassemia and no data exist on their 'return to normal' following BMT. The mean global QoL in our patient cohort was good (mean 76.4) and 63% of patients enjoyed a very good QoL. Occurrence of chronic GVHD is expected to have a detrimental impact in the QoL of patients given BMT, especially if they were originally affected by a non-malignant disorder. 17 Indeed, in the group of patients who developed this complication, the global QoL was 65.3, whereas in patients without GVHD it was 81.9. All functions were lower in the group of patients with chronic GVHD. In particular, significant differences were obtained for the physical and emotional function scales, as well as for pain and insomnia ( Table 3 ). The QoL of patients with chronic GVHD, particularly in the extensive form, may be worse than that of patients with thalassemia treated with supportive therapy. For this reason, all efforts must be spend on preventing the occurrence of this complication in patients with nonmalignant diseases. Other reports of long-term transplant survivors describe persisting fatigue as a frequent finding, capable of impeding normal functioning. 13 In our study, fatigue was reported as moderate in the group of patients with GVHD (mean 38.9) and as slight (mean 19.5) in patients without it.
When compared with data reported by Epstein et al., who administered the EORTC QLQ-C30 questionnaire to a cohort of 50 consecutive patients with different hematological diseases at 100 days after either related or unrelated BMT, our results showed higher performance on global QoL (mean 76.4 vs 50.5) and on all function scales. Additionally, the symptoms observed in our study were lower than those reported in Epstein's study. No significant differences in global QoL (mean 76.4 vs 85) and other function scales were found between our results and those of Worel et al. 10 who employed the EORTC QLQ-C30 questionnaire to evaluate 106 patients alive and in complete remission 2 years after transplantation.
In a previously published report, Arboretti et al.
12
investigated the QoL in a group of 867 thalassemia patients treated with parenteral iron-chelation therapy and blood transfusion. In this study, the perceived QoL was high in 40% of responders, moderate in 39% and fair or poor in 21% of patients. 12 Although of interest, these data are not directly comparable with ours because of the different questionnaire used to evaluate QoL. Moreover, it was not the end point of our study to compare the QoL between transplanted patients and patients on conventional transfusion and iron-chelating therapy, but to assess post transplantation QoL and the overall satisfaction felt for the decision to undergo BMT in adult thalassemia patients.
Ethical issues
Bone marrow transplantation for every disease, but in particular for a non-malignant disorder, must be respectful of all the four fundamental principles of medical ethics, including non-maleficence and beneficence. 18 In the light of these two principles, one must avoid harming the patient, or, at least, make sure that any harm incurred by the patient will be compensated by a benefit that is proportionately greater than the harm inflicted. The harm of unrelated BMT in adult class-3 thalassemia patients is significant: about 30% of these patients may die within months from transplantation. 3 Thus, the question that every adult patient must answer after a careful evaluation is whether for him/her this risk is outweighed by the benefit of BMT, which is the 70% chance of becoming independent from transfusions and iron-chelation therapy. According to the new 'liberal' paradigm, any decisions in medicine should be based on respect for patient's autonomy, which must be seen within the larger relational context of the physician-patient relationship. 18, 19 This relationship bears the phenomenological marks of a covenantal exchange rather than a contract: it draws on the physician's virtues and his ability to recognize that the patient he encounters in an obvious position of power maintains the dignity of a person. 20 Although the decision is ultimately the patient's, the physician has the responsibility to assess whether the patient is suitable for BMT. All efforts should be made by the physician to raise the patient's awareness of all the variables involved in the decision.
Limitations of this study
This study reports the clinical outcome of unrelated BMT in a cohort of adult risk class-3 thalassemia patients and provides information on modalities of communication leading to the choice of BMT, and on the perceived QoL after BMT using a method of observation. Overall, the patient sample is relatively small, even though the 27 enrolled patients represent the total number of adult class-3 thalassemia patients transplanted from an unrelated donor in Italy over the past 10 years. Another limitation is that patients were asked to recall previous experiences and that the administered items could not exhaustively explore all the communication factors involved. Because the QoL assessment was cross-sectional and not prospective, only one assessment at one point in time is reported.
